Pharmacokinetics of Drugs in Neonates: Pattern Recognition Beyond Compound Specific Observations

Current Pharmaceutical Design

Volumn 18, Issue 21, 2012, Pages 3119-3146

  Smits, Anne ^a   Kulo, Aida ^a   de Hoon, Jan N ^a   Allegaert, Karel ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Drug; Newborn; Ontogeny; Pharmacokinetics; Predictability; Variability

Indexed keywords

ACETYLSALICYLIC ACID; AMIKACIN; AMINOGLYCOSIDE; BETAMETHASONE; CREATININE; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A; CYTOCHROME P450 ISOENZYME; DIGOXIN; GLUCURONIDE; GLUCURONOSYLTRANSFERASE; GLYCOPROTEIN P; IBUPROFEN; INDOMETACIN; MICROSOME ENZYME; OROSOMUCOID; PANCREAS ENZYME; PARACETAMOL; PENICILLIN G; PROPOFOL; THIOPENTAL; TRAMADOL; VANCOMYCIN;

ANESTHESIA INDUCTION; APGAR SCORE; ARTICLE; BIRTH WEIGHT; BODY COMPOSITION; CATALYSIS; COMPUTER PROGRAM; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIURESIS; DRUG ABSORPTION; DRUG ADMINISTRATION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; DRUG TRANSFORMATION; DRUG TRANSPORT; DRUG UPTAKE; DRUG URINE LEVEL; ENZYME ACTIVITY; FIRST PASS EFFECT; GENETIC POLYMORPHISM; GESTATIONAL AGE; GLOMERULUS FILTRATION; HEMODYNAMICS; HUMAN; KIDNEY BLOOD FLOW; KIDNEY CLEARANCE; KIDNEY DYSFUNCTION; KIDNEY PERFUSION; KIDNEY TUBULE FUNCTION; LIPOPHILICITY; LIVER BLOOD FLOW; LUNG VENTILATION; MATURATION; MEMBRANE PERMEABILITY; METABOLIC CLEARANCE RATE; NEWBORN; OFF LABEL DRUG USE; ONTOGENY; ORAL DRUG ADMINISTRATION; ORGAN BLOOD FLOW; ORGAN WEIGHT; PHARMACOKINETICS; POSTNATAL GROWTH; PREMATURITY; PRENATAL DRUG EXPOSURE; PRESCRIPTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RECTAL DRUG ADMINISTRATION; RESPIRATORY DISTRESS; STOMACH EMPTYING; STOMACH PH; URINE VOLUME; VITAMIN K DEFICIENCY;

EID: 84862611371     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811209023119     Document Type: Article

References (130)

1. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kaufman RE. Developmental pharmacology: drug disposition, action, and therapy in infants and children. N Engl J Med 2003; 349: 1157-67.
2. Allegaert K, Verbesselt R, van den Anker JN, et al. Developmental pharmacology: since neonates are not just small adults. Acta Clin Belg 2008; 63: 522-30.
3. McIntyre J, Choonara I. Drug toxicity in the neonate. Biol Neonate 2004; 86: 218-21.
4. Shinwell ES, Karplus M, Reich D, et al. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. Arch Dis Child Fetal Neonatal Ed 2000; 83: F177-81.
5. Rakhmanina NY, van den Anker JN. Pharmacological research in pediatrics: from neonates to adolescents. Adv Drug Deliv Rev 2006; 58: 4-14.
6. Van den Anker JN. Pharmacokinetics and renal function in the preterm infant. Acta Paediatr 1996; 85: 1393-1399.
7. de Cock R, Piana C, Krekels EH, et al. The role of population PKPD modelling in paediatric clinical research. Eur J Clin Pharmacol 2011; 67(Suppl 1): S5-S16.
8. Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: modelling covariate effects. Eur J Pediatr 2006; 165: 819-29.
9. De Maat MM, Tijssen TA, Brüggemann RJ, Ponssen HH. Paracetamol for intravenous use in medium-and intensive care patients: pharmacokinetics and tolerance. Eur J Clin Pharmacol 2010; 66: 713-9.
10. Allegaert K, Naulaers G. Haemodynamics of intravenous paracetamol in neonates. Eur J Clin Pharmacol 2010; 66: 855-8.
11. Allegaert K, Van der Marel CD, Debeer A, et al. Pharmacokinetics of single dose intravenous propacetamol in neonates: effect of gestational age. Arch Dis Child Fetal Neonatal Ed 2004; 89: F25-8.
12. Vanderhaegen J, Naulaers G, Van Huffel S, Vanhole C, Allegaert K. Cerebral and systemic hemodynamic effects of intravenous bolus administration of propofol in neonates. Neonatology 2010; 98: 57-63.
13. Conroy S, McIntyre J, Choonara I. Unlicensed and off label drug use in neonates. Arch Dis Child Fetal Neonatal Ed 1999; 89: F142-4.
14. Ligi I, Boubred F, Grandvuillemin I, Simeoni U. Clinical research in newborn infants: difficulties and specificity. Eur J Clin Pharmacol 2011; 67(Suppl 1): S29-S32.
15. Van den Anker JN. Managing drugs safely. Semin Fetal Neonatal Med 2005; 10: 73-81.
16. Sherwin CM, Svahn S, Van der Linden A, Broadbent RS, Medlicott NJ, Reith DM. Individualised dosing of amikacin in neonates: a pharmacokinetic/pharmacodynamic analysis. Eur J Clin Pharmacol 2009; 65: 705-13.
17. Allegaert K, Sherwin CM. Amikacin in neonates: dosing recommendations should be based on both pharmacokinetics and dynamics. Singapore Med J 2010; 51: 88-9.
18. Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: general principles. Eur J Pediatr 2006; 165: 741-6.
19. Heidmets LT, Metsvaht T, Ilmoja ML, Pisarev H, Oselin K, Lutsar I. Blood loss related to participation in pharmacokinetic study in preterm neonates. Neonatology 2011; 100: 111-5.
20. Bellanti F, Della Pasqua O. Modelling and simulation as research tools in paediatric drug development. Eur J Clin Pharmacol 2011; 67(Suppl 1): 75-86.
21. Allegaert K, Verbesselt R, Rayyan M, Debeer A, de Hoon JN. Urinary metabolites to assess in vivo ontogeny of hepatic drug metabolism in early neonatal life. Methods Find Exp Clin Pharmacol 2007; 29: 251-6.
22. De Wildt SN, Kerkvliet KT, Wezenberg MG, et al. Use of saliva in therapeutic drug monitoring of caffeine in preterm infants. Ther Drug Monit 2001; 23: 250-4.
23. Bartelink IH, Rademaker CM, Schobben AF, van den Anker JN. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet 2006; 45: 1077-97.
24. Knibbe CA, Krekels EH, Danhof M. Advances in paediatric pharmacokinetics. Expert Opin Drug Metab Toxicol 2011; 7: 1-8.
25. Johnson TN, Rostami-Hodjegan A. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice. Paediatr Anaesth 2011; 21: 291-301.
26. Anderson BJ. Pediatric models for adult target-controlled infusion pumps. Paediatr Anaesth 2010; 20: 223-32.
27. Allegaert K, Anderson BJ, Cossey V, Holford NH. Limited predictability of amikacin clearance in extreme premature neonates at birth, Br J Clin Pharmacol 2006; 61: 39-48.
28. Staelens S, van den Driessche M, Barclay D, et al. Gastric emptying in healthy newborns fed an intact protein formula, a partially and an extensively hydrolysed formula. Clin Nutr 2008; 27: 264-8.
29. Sase M, Miwa I, Sumie M, Nakata M, Sugino N, Ross MG. Ontogeny of gastric emptying patterns in the human fetus. J Matern Fetal Neonatal Med 2005; 17: 213-7.
30. Ramirez A, Wong WW, Shulman JR. Factors regulating gastric emptying in preterm infants. J Pediatr 2006; 149: 475-9.
31. Gibb IA, Anderson BJ. Paracetamol (acetaminophen) pharmacodynamics: interpreting the plasma concentration. Arch Dis Child 2008; 93: 241-7.
32. Allegaert K, Daniels H, Naulaers G, Tibboel D, Devlieger H. Pharmacodynamics of chloral hydrate in former preterm infants. Eur J Pediatr 2005; 164: 403-7.
33. Huang NN, High RH. Comparison of serum levels following the administration of oral and parenteral preparations of penicillin to infants and children of various age groups. J Pediatr 1953; 42: 657-8.
34. Blake MJ, Abdel-Rahman SM, Pearce RE, Leeder JS, Kearns GL. Effect of diet on the development of drug metabolism by cytochrome P-450 enzymes in healthy infants. Pediatr Res 2006; 60: 717-23.
35. Blake MJ, Gaedigk A, Pearce RE et al. Ontogeny of dextromethorphan O-and N-demethylation in the first year of life. Clin Pharmacol Ther 2007; 81: 510-6.
36. Anderson BJ, van Lingen RA, Hansen TG, et al. Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis. Anesthesiology 2002; 96: 1336-45.
37. Allegaert K, Palmer GM, Anderson BJ. The pharmacokinetics of intravenous paracetamol in neonates: size matters most. Arch Dis Child 2011; 96: 575-80.
38. Choonara I. Ethical and safety aspects of clinical trials in neonates. Early Hum Dev 2009; 85(S10): S19-20.
39. Anderson BJ, Allegaert K. The pharmacology of general anaesthetics in the neonate. Best Pract Res Clin Anaesthesiol 2010; 98: 932-9.
40. Allegaert K, de Hoon J, Verbesselt R, Naulaers G, Murat I. Maturational pharmacokinetics of single intravenous bolus administration of propofol. Paediatr Anaesth 2007; 17: 1028-34.
41. Norman E, Westrin P, Fellman V. Placental transfer and pharmacokinetics of thiopentone in newborn infants. Arch Dis Child Fetal Neonatal Ed 2010; 95: F277-82.
42. Lingvall M, Reith D, Broadbent R. The effect of sepsis upon gentamicin pharmacokinetics in neonates. Br J Clin Pharmacol 2005; 59: 54-61.
43. Wildschut ED, AZhsman MJ, Allegaert K, Mathot RA, Tibboel D. Determinants of drug absorption in different ECMO circuits. Intensive Care Med 2010; 36: 2109-16.
44. Allegaert K, Veykemans F, Tibboel D. Clinical practice. Analgesia in neonates. Eur J Pediatr 2009; 168: 765-70.
45. Alcorn J, McNamara PJ. Ontogeny of hepatic and renal systemic clearance pathways in infants: part II. Clin Pharmacokinet 2002; 41: 1077-94.
46. Diot C, Kibleur Y, Desfrere L. Effect of ibuprofen on bilirubinalbumin binding in vitro at concentrations observed during treatment of patent ductus arteriosus. Early Hum Dev 2010; 86: 315-7.
47. Soligard HT, Nilsen OG, Bratlid D. Displacement of bilirubin form albumin by ibuprofen in vitro. Pediatr Res 2010; 67: 614-8.
48. Ueshima S, Aiba T, Ishikawa N, et al. Poor applicability of estimation method for adults to calculate unbound serum concentrations of valproic acid in epileptic neonates and infants. J Clin Pharm Ther 2009; 34: 415-22.
49. Yanni SB, Smith PB, Benjamin DK Jr, et al. Higher clearance of micafungin in neonates compared with adults: role of agedependent micafungin serum binding. Biopharm Drug Dispos 2011; 32: 222-32.
50. Pullen J, Stolk LM, Degraeuwe PL, van Tiel FH, Neef C, Zimmermann LJ. Protein binding of flucloxacillin in neonates. Ther Drug Monit 2007; 29: 279-83.
51. Chen N, Aleksa K, Woodland C, Rieder M, Koren G. Ontogeny of drug elimination by the human kidney. Pediatr Nephrol 2006; 21: 160-8.
52. Rhodin MM, Anderson BJ, Peters AM, et al. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr Nephrol 2009; 24: 67-76.
53. Koren G, James A, Perlman M. A simple method for the estimation of glomerular filtration rate by gentamicin pharmacokinetics during routine drug monitoring in the newborn. 1985; Clin Pharmacol Ther 38: 680-5.
54. Kapur G, Mattoo T, Aranda JV. Pharmacogenomics and renal drug disposition in the newborn. Semin Perinatol 2004; 28: 32-40.
55. Bueva A, Guignard JP. Renal function in preterm neonates. Pediatr Res 1994: 36: 572-7.
56. Anderson BJ, Allegaert K, van den Anker JN, Cossey V, Holford NH. Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. Br J Clin Pharmacol 2007; 63: 75-84.
57. Johnson TN, Tucker GT, Rostmai-Hodjegan A. Development of CYP2D6 and CYP3A4 in the first year of life. Clin Pharmacol Ther 2008; 83: 670-1.
58. Leeder JS, Kearns GL, Spielberg SP, van den Anker J. Understanding the relative roles of pharmacogenetics and ontogeny in pediat ric drug development and regulatory science. J Clin Pharmacol 2010; 50: 1377-87.
59. McCarver DG, Hines RN. The ontogeny of human drugmetabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. J Pharmacol Exp Ther 2002; 300: 361-6.
60. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin Pharmacokinet 1999; 36: 439-52.
61. Allegaert K, de Hoon J, Verbesselt R, et al. Intra-and interindividual variability of glucuronidation of paracetamol during repeated administration of propacetamol in neonates. Acta Paediatr 2005; 94: 1273-9.
62. Allegaert K, Vanhaesebrouck S, Verbesselt R, van den Anker JN. In vivo glucuronidation activity of drugs in neonates: extensive interindividual variability despite their young age. Ther Drug Monit 2009; 31: 411-5.
63. Welzing L, Ebenfeld S, Dlugay V, Wiesen MH, Roth B, Mueller C. Remifentanil degradation in umbilical cord blood of preterm infants. Anesthesiology 2011; 114: 570-7.
64. Anderson BJ, Pons G, Autret-Leca E, et al. Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis. Paediatr Anaesth 2005; 15: 282-92.
65. Blake MJ, Castro L, Leeder JS, Kearns GL. Ontogeny of drug metabolizing enzymes in the neonate. Semin Fetal Neonatal Med 2005; 10: 123-38.
66. Hines RN, McCarver DG. The ontogeny of human drugmetabolizing enzymes: phase I oxidative enzymes. J Pharmacol Exp Ther 2002; 300: 355-60.
67. Sweeney DE, Vallon V, Rieg T, et al. Functional maturation of drug transporters in the developing, neonatal and postnatal kidney. Mol Pharmacol 2011 Apr 14, DOI 10.1124/mol.110.070680
68. Nouri S, Mahdhaoui N, Beizig S, et al. Acute renal failure in full term neonates with perinatal asphyxia. Prospective study of 87 cases. Arch Pediatr 2008; 15: 229-35.
69. Cuzzolin L, Fanos V, Pinna B, et al. Postnatal renal function in preterm newborns: a role of diseases, drugs and therapeutic interventions. Pediatr Nephrol 2006; 21: 931-8.
70. Cataldi L, Leone R, Moretti U, et al. Potential risk factors for the development of acute renal failure in preterm newborn infants: a case-control study. Arch Dis Child Fetal Neonatal Ed 2005; 90: F514-9.
71. Fanos V, Cataldi L. Drug misadventuring in neonatal nephrology. Pediatr Med Chir 2002; 24: 150-6.
72. Longini M, Perrone S, Vezzosi P, et al. Isoprostane levels in urine of preterm newborns treated with ibuprofen for patent ductus arteriosus closure. Pediatr Nephrol 2011; 26: 105-9.
73. Antonucci R, Cuzzolin L, Arceri A, Dessi A, Fanos V. Changes in urinary PGE2 after ibuprofen treatment in preterm infants with patent ductus arteriosus. Eur J Clin Pharmacol 2009; 65: 223-30.
74. Guimaraes H, Rocha G, Tomé T, Anatolitou F, Sarafidis K, Fanos V. Non-steroid anti-inflammatory drugs in the treatment of patent ductus arteriosus in European newborns. J Matern Fetal Neonatal Med 2009; 23(Suppl 3): 77-80.
75. Allegaert K, Cossey V, Debeer A, et al. The impact of ibuprofen on renal clearance in preterm infants in independent of the gestational age. Pediatric Nephrol 2005; 20: 740-3.
76. Fanos V, Benini D, Verlato G, Errico G, Cuzzolin L. Efficacy and renal tolerability of ibuprofen vs. indomethacin in preterm infants with patent ductus arteriosus. Fundam Clin Pharmacol 2005; 19: 187-93.
77. Vieux R, Desandes R, Boubred F, et al. Ibuprofen in very preterm infants impairs renal function for the first month of life. Pediatr Nephrol 2010; 25: 267-74.
78. Allegaert K, Cossey V, Langhendries JP, Naulaers G, Vanhole C, Devlieger H, Van Overmeire B. Effects of Co-Administration of Ibuprofen-Lysine on the Pharmacokinetics of Amikacin in Preterm Infants during the First Days of Life. Biol Neonate 2004; 86: 207-11.
79. Allegaert K. The impact of ibuprofen or indomethacin on renal drug clearance in neonates. J Matern Fetal Neonatal Med 2009; 22(Suppl3): 88-91.
80. Vieux R, Hascoet JM, Merdariu D, Fresson J, Guillemin F. Glomerular filtration rate reference values in very preterm children. Pediatrics 2010; 125: e1186-92.
81. George I, Mekahli D, Rayyan M, Levtchenko E, Allegaert K. Postnatal trends in creatinemia and its covariates in extremely low birth weight (ELBW) infants. Pediatr Nephrol 2011; 26: 1843-9.
82. Zaffanello M, Bassareo PP, Cataldi L, Antonucci R, Biban P, Fanos V. Long-term effects of neonatal drugs on the kidney. J Matern Fetal Neonatal Med 2010; 23(Suppl 3): 87-9.
83. Puddu M, Fanos V, Podda F, Zaffanello M. The kidney for prenatal to adult life: perinatal programming and reduction of number of nephrons during development. Am J Nephrol 2009; 30; 162-70.
84. Allegaert K, Anderson BJ, van den Anker JN, Vanhaesebrouck S, de Zegher F. Renal drug clearance in preterm neonates: relation to prenatal growth. Ther Drug Monit 2007; 29; 284-91.
85. Thayyil S, Sheik S, Kempley ST, Sinha A. A gestation-and postnatal age-based reference chart for assessing renal function in extremely premature infants. J Perinatol 2008; 28: 226-9.
86. Iacobelli S, Bonsante F, Ferdinus C, Labenne M, Gouyon JB. Factors affecting postnatal changes in serum creatinine in preterm infants with gestational age <32 weeks. J Perinatol 2009; 29: 232-6.
87. Allegaert K, Scheers I, Cossey V, Anderson BJ. Covariates of amikacin clearance in neonates: the impact of postnatal age on predictability. Drug Metab Lett 2008; 2: 286-9.
88. Van Overmeire B, Allegaert K, Casaer A, et al. Prohylactic ibuprofen in premature infants: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2004; 364(9449): 1945-9.
89. Allegaert K, Anderson BJ, Vrancken M, et al. Impact of a paediatric vial on the magnitude of systematic medication errors in preterm neonates: amikacin as an example. Paed Perinatal Drug Ther 2006; 7: 59-63.
90. Testa M, Fanos V, Martinelli V, et al. Therapeutic drug monitoring of gentamicin in neonatal intensive care unit: experience in 68 newborns. J Chemother 2007; 19(Suppl 2): 39-41.
91. Dessi A, Salemi C, Fanos V, Cuzzolin L. Drug treatments in a neonatal setting: focus on the off-label use in the first month of life. Pharm World Sci 2010; 32: 120-4.
92. Conroy S, McIntyre J. The use of unlicensed and off-label medicines in the neonate. Semin Fetal Neonatal Med 2005; 10: 115-22.
93. De Wildt SN, Knibbe CA. Knowledge of developmental pharmacology and modeling approaches should be used to avoid useless trials in children. Eur J Clin Pharmacol 2009; 65: 849-50.
94. Wood CE, Cousins R, Zhang D, Keller-Wood M. Ontogeny of expression of organic anion transporters 1 and 3 in ovine fetal and neonatal kidney. Exp Biol Med (Maywood) 2005; 230: 668-73.
95. Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 2005; 78: 260-77.
96. De Gregori S, De Gregori M, Ranzani GN, Borghesi A, Regazzi A, Regazzi M, Stronati M. Drug transporters and renal drug disposition in the newborn. J Matern Fetal Neonatal Med 2009; 22(Suppl 3): 31-7.
97. Naulaers G, Meyns B, Miserez M, et al. Measurement of the liver tissue oxygenation by near-infrared spectroscopy. Intensive Care Med 2005; 31: 138-41.
98. Peeters MY, Allegaert K, Blussé van Oud-Alblas HJ, et al. Prediction of propofol clearance in children from an allometric model developed in rats, children and adults versus a 0.75 fixed-exponent allometric model. Clin Pharmacokinet 2010; 49: 269-75.
99. Chandra P, Brouwer KL. The complexities of hepatic drug transport: current knowledge and emerging concepts. Pharm Res 2004; 21: 719-35.
100. Lin JH, Yamazaki M. Clinical relevance of P-glycoprotein in drug therapy. Drug Metab Rev 2003; 35: 417-54.
101. Johnson TN, Thomson M. Intestinal metabolism and transport of drugs in children: the effects of age and disease. J Pediatr Gastroenterol Nutr 2008; 47: 3-10.
102. Fanta S, Jonsson S, Backman JT, Karlsson MO, Hoppu K. Developmental pharmacokinetics of ciclosporin: a population pharmacokinetic study in pediatric renal transplant candidates. Br J Clin Pharmacol 2007: 64; 772-84.
103. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metabol Dispos 1999; 27: 866-71.
104. Croom EL, Stevens JC, Hines RN, Wallace AD, Hodgson E. Human hepatic CYP2B6 developmental expression: the impact of age and genotype. Biochem Pharmacol 2009; 78: 184-90.
105. Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet 2006; 45: 931-56.
106. Bjorkman S. Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children: how accurate are available scaling methods? Clin Pharmacokinet 2006; 45: 1-11.
107. Sneyd JR, Simons PJ, Wright B. Use of proton nmr spectroscopy to measure propofol metabolites in the urine of the female Caucasian patient. Xenobiotica 1994; 24: 1021-8.
108. Allegaert K, Vancraeynest J, Rayyan M, et al. Urinary propofol metabolites in early life after single intravenous bolus. Br J Anaesth 2008; 101: 827-831.
109. Ward RM, Tamara B, Sullivan SE, et al. Single-dose, multipledose, and population pharmacokinetics of pantroprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD). Eur J Clin Pharmacol 2010; 66: 555-61.
110. Alcorn J, McNamara PJ. Pharmacokinetics in the newborn. Adv Drug Deliv Rev 2003; 55: 667-86.
111. Stamer UM, Lehnen K, Höthker F, et al. Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain 2003; 105: 231-8.
112. Stamer UM, Musshoff F, Kobilay M, et al. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes. Clin Pharmacol Ther 2007; 82: 41-7.
113. Allegaert K, van den Anker JN, de Hoon JN, et al. Covariates of tramadol disposition in the first months of life. Br J Anaesth 2008; 100: 525-32.
114. Allegaert K, van Schaik RH, Vermeersch S, et al. Postmenstrual age and CYP2D6 polymorphisms determine tramadol Odemethylation in critically ill neonates and infants. Pediatr Res 2008; 63: 674-9.
115. Kearns GL, Robinson PK, Wilson JT, et al. Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny. Clin Pharmacol Ther 2003; 74: 312-25.
116. de Wildt SN, Kearns GL, Hop WC, Murry DJ, Abdel-Rahman SM, van den Anker JN. Pharmacokinetics and metabolism of oral midazolam in preterm infants. Br J Clin Pharmacol 2002; 53: 390-2.
117. Strassburg CP, Strassburg A, Kneip S, et al. Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut 2002; 50: 259-65.
118. Miyagi SJ, Collier AC. Pediatric development of glucuronidation: the ontogeny of hepatic UGT1A4. Drug Metab Dispos 2007; 35: 1587-92.
119. Krumbiegel P, Domke S, Morseburg B, et al. Maturation of hepatosomal mono-oxygenation and glucuronidation activities in preand full-term infants as studied using the [15N]-methacetin urine test. Acta Paediatr 1997; 86: 1236-40.
120. Knibbe CA, Krekels EH, van den Anker JN, et al. Morphine glucuronidation in preterm neonates, infants and children younger than 3 years. Clin Pharmacokinet 2009; 48: 371-85.
121. Krekels EH, DeJongh J, van Lingen RA, et al. Predictive performance of a recently developed population pharmacokinetic model for morphine and its metabolites in new datasets of (preterm) neonates, infants and children. Clin Pharmacokinet 2011; 50: 51-63.
122. Allegaert K, Rochette A, Veyckemans F. Developmental pharmacology of tramadol during infancy: ontogeny, pharmacogenetics and elimination clearance. Paediatr Anaesth 2011; 21: 266-73.
123. Tremlett M, Anderson BJ, Wolf A. Pro-con debate: is codeine a drug that still has a useful role in pediatric practice? Paediatr Anaesth 2010; 20: 193-94.
124. Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeineprescribed mother. Lancet 2006; 368(9536): 704.
125. Voronov P, Przybylo HJ, Jagannathan N. Apnea in a child after oral codeine: a genetic variant-an ultra-rapid metabolizer. Paediatr Anaesth 2007; 17: 684-7.
126. Brasseur D. Paediatric research and the regulation "better medicines for the children in Europe". Eur J Clin Pharmacol 2011; 67(Suppl 1): 1-3.
127. Kulo A, Allegaert K, de Hoon J, Verbesselt R. Determination of propylene glycol in human neonates by high performance liquid chromatography with photodiode array detection. Chromatographia 2011; 73: 463-70.
128. Sumpter A, Anderson BJ. Pediatric pharmacology in the first year of life. Curr Opin Anaesthesiol 2009; 22: 469-475
129. Anderson BJ, Hansen TG. Getting the best from pediatric pharmacokinetic data. Paediatr Anaesth 2004; 14: 713-5.
130. Fanos V, Yurdakök M. Personalized neonatal medicine. J Matern Fetal Neonatal Med 2010; 23(Suppl 3): 4-6.